RET-positive Ongoing Clinical Trials
Clinical trials looking at possible next-generation RET inhibitors in all solid tumors with RET gene abnormalities:
These clinical trials are looking at the safety and efficacy of novel agents developed to overcome resistance mechanisms seen in patients who have progressed on the ‘first generation’ RET-targeting tyrosine kinase inhibitors (TKIs) Selpercatinib (Retevmo) and Pralsetinib (Gavreto).
| ClinicalTrials.gov ID | Title | Phase | Locations | Sponsor | Date Opened | Contact |
|---|---|---|---|---|---|---|
| NCT05443126 | A Study of EP0031-101 in Patients With Advanced RET-altered Malignancies | I/II |
Los Angeles California, Cleveland Ohio, Portland Oregon, Houston Texas |
Ellipses Pharma | Jul-22 | Liz@ellipses.life |
| NCT05653869 | A Study of APS03118 in Advanced Solid Tumors Harboring RET Mutations or Fusions | I |
Shanghai China |
Applied Pharmaceutical Science, Inc. | Dec-22 | liuxueying@apspharm.com, zhongjun@apspharm.com |
SOURCE: ClinicalTrials.gov
Clinical trials looking at first-generation RET inhibitors in all RET-positive solid tumors:
| ClinicalTrials.gov ID | Title | Phase | Locations | Sponsor | Date Opened | Contact |
|---|---|---|---|---|---|---|
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) | I/II | 79 locations worldwide | Blueprint Medicines Corporation | Mar-17 | studydirector@blueprintmedicines.com |
| NCT03157128 | Phase 1/2 Study of LOXO-292 in Patients with Advanced Solid Tumors, RET Fusion-positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | I/II | 84 locations world wide | Loxo Oncology | May-17 | clinicaltrials@loxooncology.com |
| NCT03157128 | Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | II | 153 locations world wide | Hoffmann-La Roche | October-20 | Global-Roche-Genentech-Trials@gene.com |
SOURCE: ClinicalTrials.gov
Clinical trials comparing first-generation RET inhibitors to standard-of-care chemotherapy in RET Fusion-positive NSCLC:
| ClinicalTrials.gov ID | Title | Phase | Locations | Sponsor | Date Opened | Contact |
|---|---|---|---|---|---|---|
| NCT04194944 | A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431) | III | 216 Locations world wide | Eli Lilly | Feb-20 | ClinicalTrials.gov@lilly.com |
| NCT04222972 | AcceleRET Lung Study of Pralsetinib for 1L RET Fusionpositive, Metastatic NSCLC | III | 58 Locations world wide | Blueprint Medicines Corporation | Jan-20 | medinfo@blueprintmedicines.com |
SOURCE: ClinicalTrials.gov
Clinical trials looking at first-generation RET inhibitors for RET-altered Thyroid Cancers:
| ClinicalTrials.gov identifier Number | Title | Phase | Locations | Sponsor | Date Opened | Contact |
|---|---|---|---|---|---|---|
| NCT04211337 | A Study of Selpercatinib (LY3527723) in Participants with RET-Mutant Thyroid Cancer (LIBRETTO-531) | III | 156 study locations worldwide | Eli Lilly | Dec-19 | ClinicalTrials.gov@lilly.com |
| NCT04759911 | Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer | II | MD Anderson | MD Anderson | Not yet recruiting | mzafereo@mdanderson.org |
| NCT04760288 | A study of Pralsetinib Versus Standard of Care for Treatment of RET-Mutated Medullary Thyroid Cancer | III | Not yet recruiting | Hoffmann-La Roche | Not yet recruiting | global-roche-genentech-trials@gene.com |
SOURCE: ClinicalTrials.gov